This study is accepting new patients by invitation only

An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial

a study on Chronic Lymphocytic Leukemia Leukemia Acute Myeloid Leukemia Multiple Myeloma Lymphoma Non-Hodgkin Lymphoma Acute Lymphoblastic Leukemia Cancer, General

Summary

Location
at UCLA
Dates
study start
estimated completion

Description

Summary

The purpose of this extension study is to provide venetoclax and obtain long-term safety data for subjects who continue to tolerate and derive benefit from receiving venetoclax in ongoing studies.

Keywords

Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Multiple Myeloma, Non-Hodgkin's Lymphoma, Acute Lymphoblastic Leukemia, Cancer, Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML), Multiple Myeloma (MM), Non-Hodgkin's Lymphoma (NHL), Acute Lymphoblastic Leukemia (ALL), Venetoclax, Leukemia, Myeloid Leukemia, Leukemia, Myeloid, Acute, Non-Hodgkin Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoid Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell

Eligibility

You can join if…

  • Subject has been enrolled and dosed in an ongoing venetoclax study and continues to tolerate and derive benefit from the study drug.
  • Male subject agrees to refrain from sperm donation.
  • Female subjects must not be pregnant or breastfeeding.

You CAN'T join if...

- None.

Locations

  • UCLA Santa Monica Hematology Oncology /ID# 210551
    Los Angeles California 90095 United States
  • University of Arizona Cancer Center - Tucson /ID# 210548
    Tucson Arizona 85724 United States

Details

Status
accepting new patients by invitation only
Start Date
Completion Date
(estimated)
Sponsor
AbbVie
Links
Related Info
ID
NCT03844048
Phase
Phase 3 research study
Study Type
Interventional
Participants
Expecting 550 study participants
Last Updated